iTrack™ Canaloplasty to be Featured in Numerous Scientific Presentations at the ASCRS 2023 Annual Meeting

2023-05-04

FREMONT, Calif.--(BUSINESS WIRE)-- Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that its proprietary iTrack™ technology portfolio for canaloplasty, a stent-free minimally invasive glaucoma procedure, will be featured in 18 scientific presentations and posters during the official program of the 2023 American Society of Cataract and Refractive Surgery (ASCRS), taking place May 5-8, 2023, in San Diego, California. A summary of the iTrack™ scientific programming at the ASCRS is outlined below: Paper Presentations “A Study of Cataract Surgery Combined with Canaloplasty and Microtrabecular Bypass Stent Surgery in Open Angle Glaucoma” Matthew S. Porter, MD; Mark J. Gallardo, MD; Addie Pederson, BA; Brandon P. Wood, MD Date: Saturday May 6, 2023 Time: 1:45-1:50pm Location: San Diego Convention Center (SDCC), Upper Level, Room 5B “Medication Burden in 3+Meds Glaucoma Eyes Following Canaloplasty and Microtrabecular Bypass Implantation Combined with Phacoemulsification” Brandon P Wood, MD; Matthew S Porter, MD; Mark J. Gallardo, MD; Addie Pederson, BA Date: Saturday May 6, 2023 Time: 1:55-2:00pm Location: San Diego Convention Center (SDCC), Upper Level, Room 5B “Performing Ab-Interno Canaloplasty Post Keratoplasty in Steroid-Induced Glaucoma Eyes – 2 Years Outcomes” Neal Rangu, BA; Umar D. Sandhu, BA; Mohsain S. Gill, MD; Kamran M. Riaz, MD; Mahmoud A. Khaimi, MD Date: Saturday May 6, 2023 Time: 2:37-2:42pm Location: San Diego Convention Center (SDCC), Upper Level, Room 5B “Longitudinal Data Registry on the Role of Canaloplasty for Treatment of Glaucoma” David M. Lubeck, MD, ABO; Nathan M Kerr, FRANZCO, MD; Ike K. Ahmed, MD, FRCSC, ABO; Keith Barton, MBBS, FRCOphth Date: Sunday May 7, 2023 Time: 10:00-10:05am Location: San Diego Convention Center (SDCC) - Upper Level, Room 5A “Endothelial Cell Density and Loss Following Ab-Interno Canaloplasty in Patients with Mild-Moderate Glaucoma as Compared to Severe Glaucoma” David M. Lubeck, MD, ABO; Robert J. Noecker, MD, MBA, ABO Date: Sunday May 7, 2023 Time: 1:30-1:35pm Location: San Diego Convention Center (SDCC) - Upper Level, Room 1B “Investigating the Consistency in Outcomes of Ab-Interno Canaloplasty as a Standalone Procedure” J. Christian Berry, MD; Mahmoud A. Khaimi, MD Date: Sunday May 7, 2023 Time: 1:45-1:50pm Location: San Diego Convention Center (SDCC) - Upper Level, Room 1B “Effective and Safety Pro Ab Interno Canaloplasty in Open-Angle Glaucoma Eyes with IOP 25 mmHg or Higher – 24-Month Outcomes” J. Christian Berry, MD; Mahmoud A. Khaimi, MD Date: Sunday May 7, 2023 Time: 1:50-1:55pm Location: San Diego Convention Center (SDCC) - Upper Level, Room 1B “A Study of Ab-Interno Canaloplasty Combined with Cataract Surgery in Eyes with Uncontrolled Vs Controlled Primary Open Angle Glaucoma” Maimunah Virk, BA; Faye Megaris, BA; Richard J. Mackool Jr., MD Date: Sunday May 7, 2023 Time: 2:15-2:20pm Location: San Diego Convention Center (SDCC) - Upper Level, Room 1B “Performing Ab-Interno Canaloplasty Post Keratoplasty – 2 Years Outcomes” Umar D. Sandhu, BA; Mohsain S. Gill, MD; Kamran M. Riaz, MD; Mahmoud A. Khaimi, MD Date: Sunday May 7, 2023 Time: 2:40 PM - 2:45 PM Location: San Diego Convention Center (SDCC) - Upper Level, Room 1B Poster Presentations: “Ab-Interno Canaloplasty (ABiC) in Angle Closure Spectrum” Jessica Hsueh, MD; Mahmoud A. Khaimi, MD “36-Month Comparison of Outcomes of Canaloplasty: Standalone or Combined with Cataract Surgery and across All Grades of Glaucoma Severity” Shamil Patel, MD; George Reiss, MD “24-Month Evaluation of Endothelial Cell Density and Loss Following Ab-Interno Canaloplasty” David M. Lubeck, MD, ABO; Robert J. Noecker, MD, MBA, ABO “Performing Ab-Interno Canaloplasty Post Keratoplasty – 2 Years Outcomes” Umar D. Sandhu, BA; Mohsain S. Gill, MD; Kamran M. Riaz, MD; Mahmoud A. Khaimi, MD “A Study of Ab-Interno Canaloplasty Performed with or without Cataract Surgery in Eyes with Primary Open Angle Glaucoma” Maimunah Virk, BA; Faye Megaris, BA; Richard J. Mackool Jr., MD “A Study of Cataract Surgery Combined with Canaloplasty and Microtrabecular Bypass Stent Surgery in Severe Open Angle Glaucoma” Addie Pederson, BA; Matthew S Porter, MD; Mark J. Gallardo, MD; Brandon P Wood, MD “3-Year Efficacy Outcomes of Canaloplasty Performed in Patients with Mild to Moderate and Severe Primary Open-Angle Glaucoma” Mark J. Gallardo, MD “Efficacy of Ab-Interno Canaloplasty Performed with or without GATT in Cases of Moderate Versus Severe Glaucoma” James Murphy, MD “36-Month Efficacy of Ab-Interno Canaloplasty for the Treatment of Open-Angle Glaucoma” Mark J. Gallardo, MD “We are proud that our world-leading canaloplasty technology, iTrack™, will be front and center at the ASCRS 2023. The iTrack-rich podium at this year’s meeting is proof that canaloplasty is increasingly recognized as a highly versatile and effective treatment in lowering IOP in mild-moderate glaucoma patients. As the podium will show, canaloplasty may also be effective in more severe stages of glaucoma, as well as fragile eyes, such as those post-keratoplasty.” The strong podium presence for canaloplasty at the ASCRS Annual Meeting coincides with the official U.S. launch of the iTrack™ Advance canaloplasty device, which will be showcased at the Nova Eye exhibit #619. More information on Nova Eye’s participation in the ASCRS Annual Meeting is available at: As recently announced, the iTrack™ Advance was granted U.S. Food and Drug Administration (FDA) 510(k) clearance in March 2023 for canaloplasty, which involves microcatheterization and viscodilation to reduce intraocular pressure (IOP) in adult patients with primary open-angle glaucoma. The ASCRS Annual Meeting is one of the world’s largest gatherings of anterior segment surgeons. All educational content of the ASCRS annual meeting is planned by its program committee. ASCRS does not endorse, promote, approve or recommend the use of any products, devices or services. ABOUT NOVA EYE MEDICAL Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand. ABOUT CANALOPLASTY First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm’s canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm’s canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm’s canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork. iTrack™ and iTrack™ Advance have a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma. The iTrack™ canaloplasty microcatheter has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma. The iTrack™ canaloplasty microcatheter is not cleared for the ab-interno surgical technique in the United States. The iTrack™ Advance canaloplasty device has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma. For additional information about the iTrack™ Advance, including safety information, please visit: Images are available at this link: